newsfilter
← Latest News
GlobeNewswire·

Pharvaris Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Enrollment completed in CHAPTER-3, a pivotal study of deucrictibant XR for prophylactic treatment of HAE attacks; topline data anticipated in 3Q2026Timeline for submission of NDA dossier of deucrictibant IR for on-demand